百令胶囊联合ACEI/ARB治疗慢性肾小球肾炎的meta分析

Meta-analysis of Bailing Capsule combined with ACEI/ARB in the treatment of chronic glomerulonephritis

目的 系统评价百令胶囊联合血管紧张素转换酶抑制剂(ACEI)或血管紧张素受体阻滞剂(ARB)治疗慢性肾小球肾炎(CGN)的效果及安全性。方法 检索知网、万方、维普、SinoMed以及PubMed、Cochrane Library等数据库建库至2022年5月百令胶囊联合ACEI/ARB治疗CGN的随机对照试验。使用Cochrane手册评估偏倚风险,使用RevMan 5.3软件进行meta分析。结果 共纳入26篇文献,2759例患者,meta分析结果显示,试验组在提高有效率[RR=1.20,95%CI(1.16,1.24),P<0.000 01],降低24 h尿蛋白定量[MD=-0.46,95%CI(-0.53,-0.39),P<0.000 01]、血肌酐[SMD=-1.18,95%CI(-1.61,-0.75),P<0.000 01]、尿素氮[SMD=-1.49,95%CI(-1.92,-1.07),P<0.000 01]方面均优于对照组,不良反应发生率差异无统计学意义[RR=1.17,95%CI(0.64,2.13),P=0.62]。结论 百令胶囊联合ACEI/ARB治疗CGN疗效优于单用ACEI/ARB,临床安全性好。

Objective To systematically evaluate the efficacy and safety of Bailing Capsule combined with angiotensin converting enzyme inhibitor(ACEI) or angiotensin receptor blocker(ARB) in the treatment of chronic glomerulonephritis(CGN). Methods The randomized controlled trial of Bailing Capsule combined with ACEI/ARB in the treatment of CGN were searched in the databases of CNKI, Wanfang, VIP, SinoMed, PubMed,Cochrane Library, etc. from database establishment to May 2022. Cochrane manual was used to evaluate the bias risk, and RevMan 5.3 software was used for meta-analysis. Results A total of 26 articles with 2759 patients were included. Meta-analysis results showed that the experimental group was superior to the control group in terms of improving the effective rate(RR=1.20, 95%CI[1.16, 1.24], P< 0.000 01), reducing the 24-hour urine protein quantification(MD=-0.46, 95%CI[-0.53,-0.39], P< 0.000 01), serum creatinine(SMD=-1.18,95%CI[-1.61,-0.75], P< 0.000 01), urea nitrogen(SMD=-1.49, 95%CI[-1.92,-1.07], P< 0.000 01). And there was no statistically significant difference in the incidence of adverse reactions(RR=1.17, 95%CI[0.64,2.13], P=0.62). Conclusion Bailing Capsule combined with ACEI/ARB is superior to ACEI/ARB alone in the treatment of CGN, with good clinical safety.